Evaluating the Effect of Concomitant Azoles on Anticoagulant Prescribing Practices in Transplant Patients: A National Survey of Clinicians.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Kristina M Burroughs, Alicia B Lichvar, Lara M Groetzinger, Edward Horn, Carlo J Iasella, Cody A Moore, Dana R Pierce, Lauren M Sacha, Ryan M Rivosecchi
{"title":"Evaluating the Effect of Concomitant Azoles on Anticoagulant Prescribing Practices in Transplant Patients: A National Survey of Clinicians.","authors":"Kristina M Burroughs, Alicia B Lichvar, Lara M Groetzinger, Edward Horn, Carlo J Iasella, Cody A Moore, Dana R Pierce, Lauren M Sacha, Ryan M Rivosecchi","doi":"10.1177/87551225251348830","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Patients undergoing transplantation experience higher rates of venous thromboembolism and non-valvular atrial fibrillation (NVAF) compared with the general population. Anticoagulation decisions in this patient population are complex. A national survey on direct-acting oral anticoagulant practices demonstrated significant heterogeneity, in the setting of drug-drug interactions. <b>Objective:</b> The aim of this study was to evaluate the anticoagulation practices of clinicians caring for solid organ transplant patients. <b>Methods:</b> A 15-question survey consisting of 7 demographic questions and 8 unique patient cases was distributed via email Listserv of several professional transplantation organizations. Each case question asked the participant to select an anticoagulant regimen depending on: (1) indication for anticoagulation, (2) renal function, and (3) drug-drug interactions. Participants selected one of the following options: apixaban, dabigatran, enoxaparin, rivaroxaban, warfarin, or write in an alternative option. Descriptive statistics were used to analyze survey results. <b>Results:</b> Fifty participants completed 4 or more (≥50%) of the case-based survey questions and were included in the analysis. Ninety-four percent of participants were pharmacists, representing 43 transplant centers. Fifty-one percent of responders preferred warfarin for the indication of NVAF. Apixaban was preferred in patients with new or previous deep vein thrombosis/pulmonary embolism (51%). Fifty-four percent of respondents preferred warfarin in questions in renal dysfunction. In scenarios involving a mild-moderate CYP3A4 inhibitor azole antifungal, 61% of respondents preferred apixaban, with 64% of those selecting a standard dose regimen (vs a reduced dose regimen). Participants preferred warfarin (57%) in scenarios with a strong CYP3A4 inhibitor. <b>Conclusion and Relevance:</b> The results of our survey demonstrated a high degree of variation when selecting anticoagulation strategies in complex clinical scenarios involving transplant patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251348830"},"PeriodicalIF":1.1000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225251348830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients undergoing transplantation experience higher rates of venous thromboembolism and non-valvular atrial fibrillation (NVAF) compared with the general population. Anticoagulation decisions in this patient population are complex. A national survey on direct-acting oral anticoagulant practices demonstrated significant heterogeneity, in the setting of drug-drug interactions. Objective: The aim of this study was to evaluate the anticoagulation practices of clinicians caring for solid organ transplant patients. Methods: A 15-question survey consisting of 7 demographic questions and 8 unique patient cases was distributed via email Listserv of several professional transplantation organizations. Each case question asked the participant to select an anticoagulant regimen depending on: (1) indication for anticoagulation, (2) renal function, and (3) drug-drug interactions. Participants selected one of the following options: apixaban, dabigatran, enoxaparin, rivaroxaban, warfarin, or write in an alternative option. Descriptive statistics were used to analyze survey results. Results: Fifty participants completed 4 or more (≥50%) of the case-based survey questions and were included in the analysis. Ninety-four percent of participants were pharmacists, representing 43 transplant centers. Fifty-one percent of responders preferred warfarin for the indication of NVAF. Apixaban was preferred in patients with new or previous deep vein thrombosis/pulmonary embolism (51%). Fifty-four percent of respondents preferred warfarin in questions in renal dysfunction. In scenarios involving a mild-moderate CYP3A4 inhibitor azole antifungal, 61% of respondents preferred apixaban, with 64% of those selecting a standard dose regimen (vs a reduced dose regimen). Participants preferred warfarin (57%) in scenarios with a strong CYP3A4 inhibitor. Conclusion and Relevance: The results of our survey demonstrated a high degree of variation when selecting anticoagulation strategies in complex clinical scenarios involving transplant patients.

评估合用唑类药物对移植患者抗凝处方的影响:一项全国临床医生调查。
背景:与普通人群相比,接受移植的患者静脉血栓栓塞和非瓣膜性心房颤动(NVAF)的发生率更高。这类患者的抗凝决定是复杂的。一项关于直接作用口服抗凝剂的全国性调查显示,在药物相互作用的情况下,存在显著的异质性。目的:本研究的目的是评价临床医生照顾实体器官移植患者的抗凝实践。方法:通过多家专业移植机构的电子邮件Listserv进行问卷调查,问卷共15个问题,包括7个人口学问题和8个独特病例。每个病例的问题都要求参与者根据以下因素选择抗凝治疗方案:(1)抗凝适应症,(2)肾功能,(3)药物-药物相互作用。参与者选择以下选项之一:阿哌沙班,达比加群,依诺肝素,利伐沙班,华法林,或写一个替代选项。采用描述性统计方法对调查结果进行分析。结果:50名参与者完成了4个或以上(≥50%)的基于病例的调查问题,并被纳入分析。94%的参与者是药剂师,代表43个移植中心。51%的应答者选择华法林作为非瓣膜性房颤的适应症。阿哌沙班优先用于新发或既往深静脉血栓/肺栓塞患者(51%)。在肾功能不全的问题中,54%的应答者首选华法林。在涉及轻度-中度CYP3A4抑制剂唑类抗真菌药物的情况下,61%的受访者选择阿哌沙班,其中64%的人选择标准剂量方案(与减少剂量方案相比)。在强CYP3A4抑制剂的情况下,参与者更倾向于华法林(57%)。结论和意义:我们的调查结果表明,在涉及移植患者的复杂临床情况下,在选择抗凝策略时存在高度差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信